Structural Biology: The Atomic Spyglass Revolutionizing Medicine
For decades, KRAS was considered one of oncology’s most difficult drug targets. In 2013, crystallographic studies revealed a previously unrecognized pocket beneath the switch-II region of KRAS G12C, providing a structural basis for mutant-selective inhibitor design.
